New Delhi: Glenmark Pharmaceuticals Inc., USA has announced the upcoming launch of its 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial. The product is bioequivalent and therapeutically equivalent to the reference listed drug by Abbott Laboratories Pharmaceutical Products Division (NDA – 019443), and will begin distribution across the United States in November 2025.
The launch marks a strategic expansion of Glenmark’s injectable portfolio, reinforcing its commitment to delivering high-quality and affordable pharmaceutical alternatives to patients in need. Glenmark’s product is approved only for the indications listed in its official label.
According to IQVIA® sales data for the 12-month period ending August 2025, the market for 8.4% Sodium Bicarbonate Injection, 50 mEq/50 mL (1 mEq/mL) — including brand and all therapeutic equivalents — recorded annual sales of approximately $63.8 million.
Marc Kikuchi, President & Business Head, North America, Glenmark Pharmaceuticals Inc., commented:
“We are pleased to announce the expansion of our injectable portfolio to include the upcoming launch of 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial, which further reinforces our dedication to bring quality and affordable alternatives to market to patients in need.”
This launch is part of Glenmark’s broader strategy to strengthen its presence in the U.S. generics market and enhance access to essential medications through cost-effective solutions.
